Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Cash from Operations: 2009-2025

Historic Cash from Operations for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to $187,180.

  • Cumberland Pharmaceuticals' Cash from Operations fell 60.64% to $187,180 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 562.80%. This contributed to the annual value of -$612,186 for FY2024, which is 110.05% down from last year.
  • As of Q3 2025, Cumberland Pharmaceuticals' Cash from Operations stood at $187,180, which was down 77.82% from $843,801 recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Cash from Operations registered a high of $5.2 million during Q2 2023, and its lowest value of -$2.1 million during Q1 2024.
  • In the last 3 years, Cumberland Pharmaceuticals' Cash from Operations had a median value of $843,801 in 2025 and averaged $946,467.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Cash from Operations spiked by 2,683.48% in 2022, and later tumbled by 842.34% in 2023.
  • Quarterly analysis of 5 years shows Cumberland Pharmaceuticals' Cash from Operations stood at $2.0 million in 2021, then spiked by 85.64% to $3.6 million in 2022, then plummeted by 71.41% to $1.0 million in 2023, then soared by 83.12% to $1.9 million in 2024, then tumbled by 60.64% to $187,180 in 2025.
  • Its last three reported values are $187,180 in Q3 2025, $843,801 for Q2 2025, and $3.9 million during Q1 2025.